Latest Share Chat

DNL.L Share News (DNL)

DNL.L Information

There is currently no data for DNL

IN BRIEF: Cambridge Cognition Hires Diurnal CFO Bungay As Non-Exec

Mon, 14th Sep 2020 13:13

Cambridge Cognition Holdings PLC - Cambridge, England-based neuroscience technology - Appoints Diurnal Group PLC Chief Financial Officer Richard Bungay as non-executive director, effective immediately. Bungay joined Diurnal at the start of 2017, moving from Mereo BioPharma Group PLC, where he had been CFO and chief operation officer. Previously, he had been CFO of Verona Pharma PLC.

Current stock price: 40.10 pence

Year-to-date change: up 43%

By Tom Waite; thomaslwaite@alliancenews.com

More News

11 Oct 2021 19:51

TRADING UPDATES: Baron Oil boosts P2478 stake amid Upland farmout pact

14 Sep 2021 17:46

TRADING UPDATES: Strong annual results from Springfield, Fiske

13 Sep 2021 20:23

IN BRIEF: Diurnal's Efmody adrenal treatment launches in UK

7 Sep 2021 16:25

UK earnings, trading statements calendar - next 7 days

1 Sep 2021 19:34

TRADING UPDATES: Power Metal hits "bullseye"; Instem makes acquisition

28 Jul 2021 18:07

TRADING UPDATES: United Oil & Gas in North Sea sale; Trifast confident

12 Jul 2021 10:10

Diurnal agrees special protocol with FDA for Chronocort study

(Sharecast News) - Specialty pharmaceutical company Diurnal announced on Monday that the US Food and Drug Administration (FDA) has agreed a special protocol assessment (SPA) for 'Chronocort', or modified-release hydrocortisone, for the design, endpoints and statistical analysis approach of a pivotal study of the product, for the treatment for congenital adrenal hyperplasia (CAH).

2 Jul 2021 10:02

Diurnal gets UK approval for 'Efmody' treatment

(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced on Friday that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for 'Efmody', or hydrocortisone modified-release hard capsules, as treatment for adult and adolescent patients with the rare congenital adrenal hyperplasia (CAH) condition.

2 Jul 2021 10:01

Latest Share Chat

DNL.L Share News (DNL)

IN BRIEF: Cambridge Cognition Hires Diurnal CFO Bungay As Non-Exec

TRADING UPDATES: Baron Oil boosts P2478 stake amid Upland farmout pact

TRADING UPDATES: Strong annual results from Springfield, Fiske

IN BRIEF: Diurnal's Efmody adrenal treatment launches in UK

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: Power Metal hits "bullseye"; Instem makes acquisition

TRADING UPDATES: United Oil & Gas in North Sea sale; Trifast confident

Diurnal agrees special protocol with FDA for Chronocort study

Diurnal gets UK approval for 'Efmody' treatment

Diurnal gets UK approval for Efmody drug following EU authorisation

TRADING UPDATES: Gaming Realms BetMGM deal; Argo bitcoin-backed loan

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

TRADING UPDATES: Odyssean IT swings to profit; BMO Cap ups dividend

IN BRIEF: Diurnal extends Citrine licensing deal for Efmody in China

IN BRIEF: Diurnal gets another patent for adrenal insufficiency asset

Diurnal granted European patent for Alkindi

Latest Share Chat

DNL.L Share News (DNL)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Cambridge Cognition Hires Diurnal CFO Bungay As Non-Exec

Login to your account

Quickpicks are a member only feature

Login to your account